🏛️ Verified NIH Record • Updated 2026-03-31
Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (SToMP-AD) Study (NCT04685590)
Phase II Clinical Trial to Evaluate the Safety and Feasibility of Senolytic Therapy in Alzheimer's Disease
🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Washington University School of Medicine
🩺 Plain-English Summary (8th-Grade Level)
The objective of the study is to determine the safety, feasibility, and efficacy of senolytics in older adults with amnestic mild cognitive impairment (MCI) or early-stage AD (Clinical Dementia Rating (CDR)=0.5 or 1) who are tau PET positive
Who can join: Review the eligibility criteria below.
Location: Wake Forest Health Sciences — Winston-Salem, North Carolina
Age range: 60 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (5 Sites)
- Wake Forest Health Sciences — Winston-Salem, North Carolina
- Fundación ACE Clinical Site — Barcelona,
- Hospital Clínic de Barcelona Site — Barcelona,
- Sant Pau Clinical Site — Barcelona,
- FISEVI Clinical Site — Seville,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Alzheimer Disease, Early Onset
- Effects of Electrical Stimulation on Verbal Learning in Typical and Atypical Alzheimer's Disease — Baltimore, Maryland
- Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease — Chandler, Arizona
- PMN310 in Patients With Early Alzheimer's Disease (PRECISE-AD) — Irvine, California
- Neuronavigation-guided FUS-induced BBB Opening in Alzheimer's Disease Patients and Its Effects on Brain Amyloid and Tau — New York, New York
- Repurposing Nucleoside Reverse Transcriptase Inhibitors for Treatment of AD — Los Angeles, California
Explore by condition: All Alzheimer Disease, Early Onset clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.